CTR9 and breast carcinoma: Kaplan-Meier analysis demonstrated that high expression levels of the Ctr9 signature strongly associates with poor overall survival in ERα-positive, lymph node-negative breast cancer patients (Fig. 4f), further highlighting the functional significance of Ctr9 in human breast cancer.